Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd announces the launch of capecitabine tablets, a generic equivalent to Genentech’s Xeloda. Capecitabine tablets are a metabolic inhibitor with antineoplastic activity indicated for the treatment of patients with adjuvant colon cancer, metastatic colorectal cancer, and metastatic breast cancer. Capecitabine tablets should be taken with water within 30 minutes after eating, and the dosage may need to be individualized to optimize patient management. Further information on dosing regimens can be found in the product’s prescribing information.
Tablets: 150 and 500 mg
For More Information: www.tevagenerics.com
Rabeprazole Sodium Delayed-Release Tablets
Torrent Pharmaceuticals, Ltd
Aciphex delayed-release tablets (Eisai, Inc)
The FDA has approved Torrent Pharmaceuticals Ltd’s rabeprazole sodium delayed-release tablets, a generic equivalent to Eisai Inc’s Aciphex delayed-release tablets. It is indicated to treat gastroesophageal reflux disease in adults and adolescents 12 years and older. It is also indicated for the healing of duodenal ulcers, Helicobacter pylori eradication to prevent duodenal ulcers, and the treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
Tablets: 20 mg
For More Information: www.torrentpharma.com
Lansoprazole Capsules, Amoxicillin Capsules, USP, and Clarithromycin Tablets, USP
PREVPAC (Takeda Pharmaceuticals, USA)
Sandoz announced the launch of lansoprazole capsules, amoxicillin capsules, USP, and clarithromycin tablets, USP—a generic version of Takeda Pharmaceuticals’ PREVPAC. It is indicated for the eradication of Helicobacter pylori infection in patients with duodenal ulcer disease. It comprises amoxicillin and clarithromycin, which are antibiotic medicines, as well as lansoprazole, a proton pump inhibitor that helps decrease the production of excess stomach acid.
Lansoprazole Capsules (500 mg), Amoxicillin Capsules (500 mg), Clarithromycin Tablets (30 mg)
For More Information: www.us.sandoz.com
Clobetasol Propionate Foam, 0.05%, Emulsion Formulation
Olux-E Foam (Prestium Pharma)
Renaissance Pharma introduces clobetasol propionate foam 0.05%, emulsion formulation, a generic equivalent to Prestium Pharma’s Olux-E Foam. It is a corticosteroid indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years and older. It should be applied to affected areas twice daily, in the morning and evening, for up to 2 consecutive weeks.
Foam: 50 and 100 g
For More Information: www.RenaissancePharmaInc.com